Editorial: outcomes following a second switch-evaluating clinical outcomes and patient perspectives in IBD

Ashish Srinivasan^{1

2

3}, Craig Haifer^{4

5}, Lena Thin^{6

7}

Affiliations

¹ Department of Gastroenterology, Eastern Health, Melbourne, VIC, Australia.
² Department of Gastroenterology, Austin Health, Melbourne, VIC, Australia.
³ Monash University, Melbourne, VIC, Australia.
⁴ Department of Gastroenterology, St Vincent's Hospital, Sydney, NSW, Australia.
⁵ The University of Sydney, Sydney, NSW, Australia.
⁶ Department of Gastroenterology, Fiona Stanley Hospital, Perth, WA, Australia.
⁷ The University of Western Australia, Perth, WA, Australia.

Editorial

Ashish Srinivasan et al. Aliment Pharmacol Ther. 2021 May.

. 2021 May;53(9):1038-1039.

doi: 10.1111/apt.16325.

Ashish Srinivasan^{1

2

3}, Craig Haifer^{4

5}, Lena Thin^{6

7}

¹ Department of Gastroenterology, Eastern Health, Melbourne, VIC, Australia.
² Department of Gastroenterology, Austin Health, Melbourne, VIC, Australia.
³ Monash University, Melbourne, VIC, Australia.
⁴ Department of Gastroenterology, St Vincent's Hospital, Sydney, NSW, Australia.
⁵ The University of Sydney, Sydney, NSW, Australia.
⁶ Department of Gastroenterology, Fiona Stanley Hospital, Perth, WA, Australia.
⁷ The University of Western Australia, Perth, WA, Australia.

No abstract available

Comment on

Outcomes after double switching from originator Infliximab to biosimilar CT-P13 and biosimilar SB2 in patients with inflammatory bowel disease: a 12-month prospective cohort study.
Trystram N, Abitbol V, Tannoury J, Lecomte M, Assaraf J, Malamut G, Gagnière C, Barré A, Sobhani I, Chaussade S, Amiot A. Trystram N, et al. Aliment Pharmacol Ther. 2021 Apr;53(8):887-899. doi: 10.1111/apt.16312. Epub 2021 Mar 1. Aliment Pharmacol Ther. 2021. PMID: 33647174

1. O'Callaghan J, Barry SP, Bermingham M, Morris JM, Griffin BT. Regulation of biosimilar medicines and current perspectives on interchangeability and policy. Eur J Clin Pharmacol. 2019;75:1-11.
1. Jørgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389:2304-2316.
1. Haifer C, Srinivasan A, An Y-K, et al. Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study. Med J Aust. 2021;214:128-133.
1. Fischer S, Cohnen S, Klenske E, et al. Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab. Therap Adv Gastroenterol. 2021;14:1756284820982802.
1. Trystram N, Abitbol V, Tannoury J, et al. Outcomes after double switching from originator Infliximab to biosimilar CT-P13 and biosimilar SB2 in patients with inflammatory bowel disease: a 12-month prospective cohort study. Aliment Pharmacol Ther. 2021;53:887-899.